Logo image of OVXA.I

OVOCA BIO PLC (OVXA.I) Stock Fundamental Analysis

DUB:OVXA - Euronext Dublin - IE00B4XVDC01 - Common Stock - Currency: EUR

0.0105  -0.01 (-46.15%)

Fundamental Rating

2

OVXA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 51 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for OVXA as it has an excellent financial health rating, but there are worries on the profitability. OVXA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OVXA has reported negative net income.
OVXA had a positive operating cash flow in the past year.
In the past 5 years OVXA always reported negative net income.
OVXA had negative operating cash flow in 4 of the past 5 years.
OVXA.I Yearly Net Income VS EBIT VS OCF VS FCFOVXA.I Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M

1.2 Ratios

OVXA's Return On Assets of -151.63% is on the low side compared to the rest of the industry. OVXA is outperformed by 88.24% of its industry peers.
OVXA has a Return On Equity of -210.00%. This is amonst the worse of the industry: OVXA underperforms 80.39% of its industry peers.
Industry RankSector Rank
ROA -151.63%
ROE -210%
ROIC N/A
ROA(3y)-77.44%
ROA(5y)-50.21%
ROE(3y)-100.76%
ROE(5y)-64.38%
ROIC(3y)N/A
ROIC(5y)N/A
OVXA.I Yearly ROA, ROE, ROICOVXA.I Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

OVXA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVXA.I Yearly Profit, Operating, Gross MarginsOVXA.I Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

OVXA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OVXA has been increased compared to 5 years ago.
OVXA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OVXA.I Yearly Shares OutstandingOVXA.I Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
OVXA.I Yearly Total Debt VS Total AssetsOVXA.I Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -5.15, we must say that OVXA is in the distress zone and has some risk of bankruptcy.
OVXA has a Altman-Z score of -5.15. This is in the lower half of the industry: OVXA underperforms 74.51% of its industry peers.
OVXA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -5.15
ROIC/WACCN/A
WACCN/A
OVXA.I Yearly LT Debt VS Equity VS FCFOVXA.I Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M 20M

2.3 Liquidity

OVXA has a Current Ratio of 6.86. This indicates that OVXA is financially healthy and has no problem in meeting its short term obligations.
OVXA's Current ratio of 6.86 is amongst the best of the industry. OVXA outperforms 100.00% of its industry peers.
OVXA has a Quick Ratio of 6.86. This indicates that OVXA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.86, OVXA belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.86
Quick Ratio 6.86
OVXA.I Yearly Current Assets VS Current LiabilitesOVXA.I Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.01% over the past year.
EPS 1Y (TTM)9.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

OVXA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVXA.I Price Earnings VS Forward Price EarningsOVXA.I Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, OVXA is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.3
EV/EBITDA N/A
OVXA.I Per share dataOVXA.I EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OVXA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OVOCA BIO PLC

DUB:OVXA (4/28/2025, 7:00:00 PM)

0.0105

-0.01 (-46.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners44.67%
Ins Owner ChangeN/A
Market Cap928.83K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 2.3
P/OCF 2.3
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY43.5%
OCF(TTM)0
OCFY43.5%
SpS0
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -151.63%
ROE -210%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.44%
ROA(5y)-50.21%
ROE(3y)-100.76%
ROE(5y)-64.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.86
Quick Ratio 6.86
Altman-Z -5.15
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y78.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.3%
OCF growth 3YN/A
OCF growth 5YN/A